Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2023 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar forecasts that the biotechnology company will earn $0.16 per share for the quarter. SVB Leerink has a "Market Perform" rating and a $31.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($0.86) per share. SVB Leerink also issued estimates for Arrowhead Pharmaceuticals' Q2 2023 earnings at $0.16 EPS and FY2023 earnings at $0.62 EPS.

Other research analysts have also recently issued reports about the company. The Goldman Sachs Group reissued a "buy" rating and issued a $66.00 target price (up from $65.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 30th. Jefferies Financial Group decreased their target price on Arrowhead Pharmaceuticals from $92.00 to $75.00 and set a "buy" rating for the company in a research note on Tuesday, November 29th. Piper Sandler reduced their price objective on Arrowhead Pharmaceuticals from $64.00 to $55.00 in a research report on Monday, January 9th. B. Riley reduced their price objective on Arrowhead Pharmaceuticals from $65.00 to $59.00 and set a "buy" rating for the company in a research report on Wednesday, November 30th. Finally, Morgan Stanley reduced their price objective on Arrowhead Pharmaceuticals from $41.00 to $37.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 29th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $59.22.

Arrowhead Pharmaceuticals Trading Up 3.7 %

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last posted its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.24). Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative return on equity of 40.23%. The business had revenue of $31.58 million during the quarter, compared to analyst estimates of $107.60 million.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ARWR. First Horizon Advisors Inc. bought a new stake in Arrowhead Pharmaceuticals in the second quarter valued at approximately $27,000. Neo Ivy Capital Management bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $33,000. Advisors Asset Management Inc. raised its stake in Arrowhead Pharmaceuticals by 94.6% in the first quarter. Advisors Asset Management Inc. now owns 720 shares of the biotechnology company's stock valued at $33,000 after buying an additional 350 shares during the period. Finally, Wipfli Financial Advisors LLC bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at approximately $39,000. Institutional investors own 65.46% of the company's stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider Martin Javier San sold 19,500 shares of the stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $29.99, for a total transaction of $584,805.00. Following the completion of the transaction, the insider now directly owns 91,500 shares of the company's stock, valued at $2,744,085. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Arrowhead Pharmaceuticals news, Director William D. Waddill sold 3,200 shares of the company's stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $30.00, for a total value of $96,000.00. Following the sale, the director now owns 28,950 shares in the company, valued at $868,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Martin Javier San sold 19,500 shares of the company's stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $29.99, for a total value of $584,805.00. Following the completion of the sale, the insider now owns 91,500 shares in the company, valued at approximately $2,744,085. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,966 shares of company stock valued at $4,050,435. Insiders own 3.20% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

(Get Rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.

See Also

• Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
• High-Yield, Deep-Value Verizon Puts In A Bottom
• Can Coty Stock Emerge in 2023 With Upside
• Should You Bet Against The Nasdaq 100 With This Inverse ETF?
• Insiders Buy Archer Aviation, Is This Stock About To Take Off?
• Intuit Is About To Make a Move, But Which Way?

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.